Preclinical Testing News and Research

RSS

New funding to accelerate development of potential anti-cancer compound into the clinic

For the past few decades, Dr. Iwao Ojima has been working in his Stony Brook University Department of Chemistry Laboratory and through the Institute of Chemical Biology & Drug Discovery (ICB&DD) to develop next-generation anti-cancer agents.

28 Feb 2023

EIT-based imaging technology for non-invasive anisotropic transmembrane transport of cell-spheroid

The cell membrane has numerous channels for the transport of various substances, including ions, between the cell and its environment.

21 Feb 2023

Ketamine appears to hold promise in treating cocaine-use disorders

As cocaine use continues to climb across the United States, scientists have struggled to develop an effective pharmacological approach to treat the devastating disorder.

20 Feb 2023

CuSTOM; Creating a healthier society by accelerating the translation of organoid technology

In this interview, we speak to Magdalena Kasendra at the CuSTOM Accelerator, about the organoid technology and how it has the power the revolutionize healthcare.

From Society for Laboratory Automation and Screening (SLAS) 1 Feb 2023

Phase I trial results from AdaptVac's COVID capsid virus-like particle vaccine

In a recent study published in The Lancet Microbe journal, researchers described the effectiveness of a modular capsid virus-like coronavirus disease 2019 (COVID-19) vaccination.

22 Jan 2023

RNA-targeting CRISPR technology alleviates disease-related phenotypes in Huntington’s models

Huntington's disease (HD) is a neurological disorder that causes progressive loss of movement, coordination and cognitive function.

12 Dec 2022

Using human iPSC-derived cells to revolutionize the field of neurodegenerative disease

In this interview, we speak to Axol Bioscience about their human iPSC-derived cells and how they have the potential to revolutionize the field of neurodegenerative disease.

From Axol Bioscience Ltd 28 Nov 2022

Creating New Targeted Antibacterial Products to Help Tackle Antimicrobial Resistance

We speak to Matthew Dunne, Director for Drug Discovery at Micreos Pharmaceuticals, about the importance of creating new targeted antibacterial products.

22 Nov 2022

Scientists develop and test a new model of traumatic brain injury in zebrafish

A group of scientists, which included researchers from the Ural Federal University (UrFU), have developed and successfully tested a new model of traumatic brain injury (TBI) in zebrafish.

15 Sep 2022

CRISPR genome-editing technology can be used as a tool to discover RNA therapeutics for lung cancer

An international team of scientists have demonstrated for the first time that CRISPR genome-editing technology can be used as a tool to find new gene therapies for lung cancer.

24 Aug 2022

IU researchers evaluate the efficacy of a failed clinical trial drug for Alzheimer's using rigorous pipeline

Most drugs developed to treat Alzheimer's disease have for years been ineffective in clinical trials. Researchers from Indiana University School of Medicine recently evaluated the efficacy of a failed clinical trial drug using their rigorous pipeline.

25 Jul 2022

New mouse model faithfully mimics brain damage caused by severe Rift Valley Fever virus infection

A new mouse model identified by virologists from the University of Pittsburgh might revolutionize development of therapies targeting brain inflammation caused by Rift Valley Fever virus (RVFV).

15 Jul 2022

Innovative strategy for treating non-small cell lung cancer when radiotherapy fails

Lung cancer is the most common cancer in the world, with 2.2 million new cases and around 1.8 million deaths in 2020 alone.

4 Jul 2022

Researchers create first bona fide mouse model of Merkel cell carcinoma

A team of researchers at the University of Michigan Rogel Cancer Center were the first to generate a bona fide mouse model of a Merkel cell carcinoma, a rare and potentially aggressive form of skin cancer.

15 Jun 2022

Scientists create a bioengineered 3D model that mimics the biology of two rare neuromuscular diseases

A scientific team supported by the National Institutes of Health has created a tiny, bioengineered 3-D model that mimics the biology of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy, a pair of rare, devastating neuromuscular diseases.

19 Apr 2022

INRS professor developing a glycoconjugate vaccine for melioidosis

The threat from Melioidosis is real. The bacterium that causes this infectious multisymptom illness is resistant to antibiotics, making diagnosis and treatment more complex and resulting in a mortality rate of up to 50%.

24 Mar 2022

CD63-expressing extracellular vesicles neutralize SARS-CoV-2 variants of concern

Researchers evaluate antiviral effects of CD63 tetraspanin extracellular vesicles against SARS-CoV-2 and HIV-1.

22 Mar 2022

Study suggests synthetic SARS-CoV-2 S glycoprotein coated lipid vesicles are an effective vaccine candidate

In a new study, a team of researchers developed a vaccine candidate with the SARS-CoV-2 spike (S) glycoprotein coated onto lipid vesicles which resembles virus-like particles.

26 Jan 2022

Genome editing in vascular endothelial cells made possible with a powerful new delivery system

Northwestern Medicine scientists developed a unique nanoparticle to deliver genome editing technology, including CRISPR/Cas9, to endothelial cells, which line blood vessel walls.

16 Jan 2022

Unique nanoparticle can deliver genome editing technology to endothelial cells

The lab of Youyang Zhao, PhD, from Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago developed a unique nanoparticle to deliver genome editing technology, including CRISPR/Cas9, to endothelial cells, which are cells that line blood vessel walls.

4 Jan 2022